A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention

Revankar N, Patterson J, Kadambi A, Raymond V, El-Hadi W

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.3810/pgm.2013.07.2686

Indexing Status
Subject indexing assigned by NLM

MeSH
Aged; Anticoagulants /economics /therapeutic use; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Canada; Cost-Benefit Analysis; Decision Trees; Drug Administration Schedule; Enoxaparin /economics /therapeutic use; Female; Health Care Costs; Humans; Male; Markov Chains; Models, Economic; Postoperative Complications /economics /prevention & control; Pyrazoles /economics /therapeutic use; Pyridones /economics /therapeutic use; Quality-Adjusted Life Years; Venous Thromboembolism /economics /etiology /prevention & control

AccessionNumber
22013038097

Date bibliographic record published
30/10/2013